Extremely Small 20-mm Versus Standard-Size Balloon-Expandable Transcatheter Heart Valves

Taishi Okuno MD , Masaki Izumo MD , Kai Takahiko MD , Shingo Kuwata MD , Masashi Koga MD , Yoshihiro J. Akashi MD , Shinichi Shirai MD , Yusuke Watanabe MD , Toru Naganuma MD , Norio Tada MD , Futoshi Yamanaka MD , Masahiko Noguchi MD , Hiroshi Ueno MD , Yohei Ohno MD , Hidetaka Nishina MD , Kensuke Takagi MD , Masahiko Asami MD , Kazuki Mizutani MD , Fumiaki Yashima MD , Toshiaki Otsuka MD , Kentaro Hayashida MD
{"title":"Extremely Small 20-mm Versus Standard-Size Balloon-Expandable Transcatheter Heart Valves","authors":"Taishi Okuno MD ,&nbsp;Masaki Izumo MD ,&nbsp;Kai Takahiko MD ,&nbsp;Shingo Kuwata MD ,&nbsp;Masashi Koga MD ,&nbsp;Yoshihiro J. Akashi MD ,&nbsp;Shinichi Shirai MD ,&nbsp;Yusuke Watanabe MD ,&nbsp;Toru Naganuma MD ,&nbsp;Norio Tada MD ,&nbsp;Futoshi Yamanaka MD ,&nbsp;Masahiko Noguchi MD ,&nbsp;Hiroshi Ueno MD ,&nbsp;Yohei Ohno MD ,&nbsp;Hidetaka Nishina MD ,&nbsp;Kensuke Takagi MD ,&nbsp;Masahiko Asami MD ,&nbsp;Kazuki Mizutani MD ,&nbsp;Fumiaki Yashima MD ,&nbsp;Toshiaki Otsuka MD ,&nbsp;Kentaro Hayashida MD","doi":"10.1016/j.jacasi.2024.09.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The 20-mm balloon-expandable transcatheter heart valve (THV) represents the smallest available option for transcatheter aortic valve replacement (TAVR). Its current underutilization stems from concerns regarding prosthesis-patient mismatch, durability, and potential adverse outcomes.</div></div><div><h3>Objectives</h3><div>The purpose of this study was to compare the long-term outcomes between the 20-mm balloon-expandable THVs and standard-size balloon-expandable THVs.</div></div><div><h3>Methods</h3><div>Patients who underwent transfemoral TAVR with SAPIEN THVs were sourced from the OCEAN-TAVI (Optimized Transcatheter Valvular Intervention) registry, an ongoing, multicenter cohort study that has enrolled over 7,000 TAVR patients in Japan. A 1:3 propensity-matched analysis, based on 24 baseline clinical and echocardiographic variables, was used to contrast the 20-mm with &gt;20-mm balloon-expandable THVs.</div></div><div><h3>Results</h3><div>Of 5,086 eligible patients, 284 (5.6%) received the 20-mm balloon-expandable THV. After propensity-matching, the 20-mm THV group (n = 276) and the &gt;20-mm THV group (n = 828) demonstrated balanced baseline characteristics, with an absolute standardized difference &lt;0.10. The average follow-up duration for patients who were alive was 955 ± 512 days, and the average time to death was 584 ± 543 days. The 20-mm group showed a higher frequency of prosthesis-patient mismatch (PPM) (moderate PPM: 29.2% vs 10.8%; severe PPM: 4.9% vs 1.5%; <em>P &lt;</em> 0.001). Over a 5-year period, all-cause mortality and heart failure rehospitalization rates were comparable between the 2 groups (all-cause mortality: 34.2% vs 38.0%; HR: 1.01; 95% CI: 0.74-1.37; <em>P =</em> 0.970; heart failure rehospitalization: 15.2% vs 16.3%; HR: 0.81; 95% CI: 0.50-1.29; <em>P =</em> 0.371).</div></div><div><h3>Conclusions</h3><div>This registry-based study suggests that the initially observed inferior forward hemodynamics associated with the 20-mm THV do not translate into heightened long-term mortality or heart failure rehospitalization risks. (The OCEAN-TAVI registry [Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation]; <span><span>UMINID:000020423</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":73529,"journal":{"name":"JACC. Asia","volume":"5 2","pages":"Pages 245-254"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JACC. Asia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S277237472400351X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The 20-mm balloon-expandable transcatheter heart valve (THV) represents the smallest available option for transcatheter aortic valve replacement (TAVR). Its current underutilization stems from concerns regarding prosthesis-patient mismatch, durability, and potential adverse outcomes.

Objectives

The purpose of this study was to compare the long-term outcomes between the 20-mm balloon-expandable THVs and standard-size balloon-expandable THVs.

Methods

Patients who underwent transfemoral TAVR with SAPIEN THVs were sourced from the OCEAN-TAVI (Optimized Transcatheter Valvular Intervention) registry, an ongoing, multicenter cohort study that has enrolled over 7,000 TAVR patients in Japan. A 1:3 propensity-matched analysis, based on 24 baseline clinical and echocardiographic variables, was used to contrast the 20-mm with >20-mm balloon-expandable THVs.

Results

Of 5,086 eligible patients, 284 (5.6%) received the 20-mm balloon-expandable THV. After propensity-matching, the 20-mm THV group (n = 276) and the >20-mm THV group (n = 828) demonstrated balanced baseline characteristics, with an absolute standardized difference <0.10. The average follow-up duration for patients who were alive was 955 ± 512 days, and the average time to death was 584 ± 543 days. The 20-mm group showed a higher frequency of prosthesis-patient mismatch (PPM) (moderate PPM: 29.2% vs 10.8%; severe PPM: 4.9% vs 1.5%; P < 0.001). Over a 5-year period, all-cause mortality and heart failure rehospitalization rates were comparable between the 2 groups (all-cause mortality: 34.2% vs 38.0%; HR: 1.01; 95% CI: 0.74-1.37; P = 0.970; heart failure rehospitalization: 15.2% vs 16.3%; HR: 0.81; 95% CI: 0.50-1.29; P = 0.371).

Conclusions

This registry-based study suggests that the initially observed inferior forward hemodynamics associated with the 20-mm THV do not translate into heightened long-term mortality or heart failure rehospitalization risks. (The OCEAN-TAVI registry [Optimized Transcatheter Valvular Intervention-Transcatheter Aortic Valve Implantation]; UMINID:000020423)
极小20毫米与标准尺寸球囊可扩张经导管心脏瓣膜比较
20mm球囊可扩张经导管心脏瓣膜(THV)是经导管主动脉瓣置换术(TAVR)中最小的可用选择。其目前的利用不足源于对假体与患者不匹配、耐用性和潜在不良后果的担忧。目的本研究的目的是比较20mm球囊膨胀性thv和标准尺寸球囊膨胀性thv的长期疗效。采用SAPIEN thv进行经股TAVR的患者来自OCEAN-TAVI(优化经导管瓣膜介入)注册,这是一项正在进行的多中心队列研究,在日本招募了7000多名TAVR患者。基于24个基线临床和超声心动图变量,采用1:3倾向匹配分析,对比20mm和20mm球囊可扩张thv。结果在5086例符合条件的患者中,284例(5.6%)接受了20 mm球囊膨胀性THV。经过倾向匹配,20毫米THV组(n = 276)和20毫米THV组(n = 828)表现出平衡的基线特征,绝对标准化差为0.10。存活患者平均随访时间为955±512天,至死亡平均随访时间为584±543天。20 mm组假体-患者不匹配(PPM)的频率更高(中度PPM: 29.2% vs 10.8%;严重PPM: 4.9% vs 1.5%;P & lt;0.001)。在5年期间,两组的全因死亡率和心力衰竭再住院率具有可比性(全因死亡率:34.2% vs 38.0%;人力资源:1.01;95% ci: 0.74-1.37;P = 0.970;心力衰竭再住院:15.2% vs 16.3%;人力资源:0.81;95% ci: 0.50-1.29;P = 0.371)。结论:这项基于登记的研究表明,最初观察到的与20mm THV相关的较差的前向血流动力学并不转化为长期死亡率或心力衰竭再住院风险的增加。OCEAN-TAVI注册表[经导管瓣膜介入-经导管主动脉瓣植入术];UMINID: 000020423)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JACC. Asia
JACC. Asia Cardiology and Cardiovascular Medicine
CiteScore
4.00
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信